Methods for treating diseases associated with respiratory viruses

Abstract

The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

What is claimed: 
     
         1 . A method of treating one or more symptoms of a SARS-Coronavirus-2 (SARS-CoV-2) infection in a patient, comprising administering to the patient a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition. 
     
     
         2 . The method of  claim 1 , wherein the one or more symptoms are selected from the group consisting of acute respiratory distress syndrome (ARDS), acute lung injury (ALI), interstitial lung disease, pulmonary fibrosis, pneumonia, reactive airway disease syndrome, respiratory distress requiring supplemental oxygen, long COVID and combinations thereof. 
     
     
         4 . The method of  claim 1 , wherein the one or more symptoms are selected from the group consisting of fatigue, shortness of breath or difficulty breathing, low exercise tolerance, low blood oxygen saturation, cough, sore throat, stuffy or runny nose, joint pain, chest pain, tightness or discomfort, muscle pain, muscle weakness, fever, heart palpitations, difficulty thinking and/or concentrating, depression and combinations thereof. 
     
     
         5 . The method of  claim 4 , wherein the patient has experienced the one or more symptoms for at least four weeks, at least one month, at least two months, or at least three months. 
     
     
         6 . The method of  claim 1 , wherein the administration results in an outcome selected from the group consisting of reduced ventilator time, reduced mortality, improvement in oxygenation parameters, reduced time to resolution of one or more respiratory symptoms, improved pulmonary function, and combinations thereof. 
     
     
         7 . The method of  claim 1 , wherein, after the administration, the patient achieves improvement on the World Health Organization COVID-19 ordinal scale of at least 4, at least 3, at least 2, or at least 1. 
     
     
         8 . The method of  claim 1 , wherein the composition is administered in a form suitable for administration to the lungs. 
     
     
         9 . The method of  claim 8 , wherein the composition is administered in a nebulized form at a dose of 8 milliliters, quater in die, for five days. 
     
     
         10 . The method of  claim 1 , wherein the composition comprises DA-DKP. 
     
     
         11 . The method of  claim 10 , wherein the composition further comprises N-acetyl-tryptophan (NAT), caprylic acid, caprylate or combinations thereof. 
     
     
         12 . A method of treating inflammation associated with a SARS-Coronavirus-2 (SARS-CoV-2) infection in a patient, comprising administering to the patient a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition. 
     
     
         13 . The method of  claim 12 , wherein the inflammation is of a tissue selected from the group consisting of lung, brain, heart, kidney, blood vessel, skin, nerve, and combinations thereof. 
     
     
         14 . The method of  claim 12 , wherein the inflammation causes a symptom selected from the group consisting of fatigue, shortness of breath or difficulty breathing, low exercise tolerance, low blood oxygen saturation, cough, sore throat, stuffy or runny nose, joint pain, chest pain tightness or discomfort, muscle pain, muscle weakness, fever, heart palpitations, difficulty thinking and/or concentrating, depression, and combinations thereof. 
     
     
         15 . The method of  claim 14 , wherein the patient has experienced the symptom for at least four weeks, at least one month, at least two months, or at least three months. 
     
     
         16 . The method of  claim 12 , wherein administration results in an outcome selected from the group consisting of reduced ventilator time, reduced mortality, improvement in oxygenation parameters, reduced time to resolution of one or more respiratory symptoms, improved pulmonary function, and combinations thereof. 
     
     
         17 . The method of  claim 12 , wherein, after the administration, the patient achieves improvement on the World Health Organization COVID-19 ordinal scale of at least 4, at least 3, at least 2, or at least 1. 
     
     
         18 . The method of  claim 12 , wherein the patient has or had respiratory distress requiring supplemental oxygen caused by SARS-Coronavirus-2 (SARS-CoV-2) infection. 
     
     
         19 . The method of  claim 12 , wherein the composition is administered in a form suitable for administration to the lungs. 
     
     
         20 . The method of  claim 19 , wherein the composition is administered in a nebulized form at a dose of 8 milliliters quater in die for five days.